A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs ELND 005 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Transition Therapeutics
- 31 Jul 2017 This trial has been completed in UK (on 2015-08-18) , according to European Clinical Trials Database.
- 08 Jul 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 08 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.